ADHD

Misinformation about ADHD impacts treatment and self-perception. This Special Report clarifies misconceptions, promotes understanding, and supports informed care for individuals with ADHD.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

Discover how best to approach ADHD assessments and utilize tools such as the Mentavi Diagnostic Evaluation, which can help improve patient care and reduce stigma.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

A recent study reveals higher substance use disorder rates in individuals with ADHD, highlighting significant sex differences and the impact of comorbid psychiatric conditions.

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the FDA's claims linking acetaminophen use in pregnancy to autism and ADHD, advocating for informed maternal care.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Our August theme: the complexities of ADHD, including assessment, treatment options, and comorbidities. Share your insights!

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Cingulate secures a $4.3 million FDA fee waiver for its innovative ADHD treatment, CTx-1301, enhancing patient care with extended efficacy.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

Marc Potenza, PhD, MD, explores the impact of online social activity on ADHD symptoms in adolescents, revealing significant gender differences in brain development and attention.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Panelists discuss ADHD nonstimulant medication options with detailed clinical considerations.

Panelists discuss how comprehensive ADHD treatment approaches emphasize combination therapy and immediate implementation.

Panelists discuss the critical role of pediatricians in attention-deficity/hyperactivity disorder (ADHD) diagnosis and treatment challenges.

Panelists discuss how attention-deficity/hyperactivity disorder (ADHD) risk factors include genetic, environmental, and socioeconomic influences.

New research reveals the complex relationship between ADHD and bipolar disorder, highlighting genetic overlaps and treatment considerations for effective management.

Panelists discuss how an attention-deficity/hyperactivity disorder (ADHD) diagnosis impacts families through stress and challenges but can also provide relief and understanding. They address quality-of-life effects including academic performance, family functioning, driving safety, and the need for structure and routine management.

Panelists discuss how diagnostic challenges include ensuring symptoms are developmentally appropriate, distinguishing attention-deficity/hyperactivity disorder (ADHD) from other conditions such as depression and anxiety and using tools such as the NICHQ Vanderbilt Assessment Scales and Connors Comprehensive Behavior Rating Scale to assess symptoms across multiple settings.